Clinical Trial Detail

NCT ID NCT04305041
Title Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

melanoma

Therapies

MK-1308 + MK-7684 + Pembrolizumab

Lenvatinib + MK-1308 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.